Cargando…

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients

Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor prognosis; survival rates are likely to be lower with TNBC compared to other breast cancer subgroups. For this disease, systemic adjuvant chemotherapy regimens often yield suboptimal clinical results. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Absmaier, Magdalena, Napieralski, Rudolf, Schuster, Tibor, Aubele, Michaela, Walch, Axel, Magdolen, Viktor, Dorn, Julia, Gross, Eva, Harbeck, Nadia, Noske, Aurelia, Kiechle, Marion, Schmitt, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807037/ https://www.ncbi.nlm.nih.gov/pubmed/29328369 http://dx.doi.org/10.3892/ijo.2018.4241

Ejemplares similares

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
por: Aubele, Michaela, et al.
Publicado: (2017)

Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
por: Schricker, Gabriele, et al.
Publicado: (2018)

Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221
por: Falkenberg, Natalie, et al.
Publicado: (2015)

Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies
por: Schmitt, Manfred, et al.
Publicado: (2013)

A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression
por: Liu, Yueyang, et al.
Publicado: (2022)

uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R
por: Huber, Michaela C., et al.
Publicado: (2016)

Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast Cancer
por: Lehner, Anna, et al.
Publicado: (2013)

Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer
por: Huber, Michaela C., et al.
Publicado: (2016)

Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients
por: Gong, Weiwei, et al.
Publicado: (2020)

Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer
por: Gong, Weiwei, et al.
Publicado: (2020)

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer
por: Geng, Xiaocong, et al.
Publicado: (2017)

Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers
por: Gross, E, et al.
Publicado: (2013)

Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer
por: Gong, Weiwei, et al.
Publicado: (2019)

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
por: Gross, Eva, et al.
Publicado: (2016)

OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery
por: DORN, JULIA, et al.
Publicado: (2015)

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs
por: Ataseven, Beyhan, et al.
Publicado: (2014)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Pitx2 in Embryonic and Adult Myogenesis
por: Hernandez-Torres, Francisco, et al.
Publicado: (2017)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Regulation of Motility of Myogenic Cells in Filling Limb Muscle Anlagen by Pitx2
por: Campbell, Adam L., et al.
Publicado: (2012)

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
por: Loibl, Sibylle, et al.
Publicado: (2008)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

PITX1 plays essential functions in cancer
por: Zhao, Jingpu, et al.
Publicado: (2023)

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer
por: Wang, Ping, et al.
Publicado: (2018)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Heterogeneous Chromosomal Aberrations in Intraductal Breast Lesions Adjacent to Invasive Carcinoma
por: Aubele, Michaela, et al.
Publicado: (2000)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients
por: Dietrich, Dimo, et al.
Publicado: (2010)

FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
por: Xu, Y. L., et al.
Publicado: (2017)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Transgenic Insights Linking Pitx2 and Atrial Arrhythmias
por: Franco, Diego, et al.
Publicado: (2012)

Multiple Roles of Pitx2 in Cardiac Development and Disease
por: Franco, Diego, et al.
Publicado: (2017)

A PITX2 splice-site mutation in a family with Axenfeld-Rieger syndrome leads to decreased expression of nuclear PITX2 protein
por: Zhang, Feng, et al.
Publicado: (2021)

Loss of Abdominal Muscle in Pitx2 Mutants Associated with Altered Axial Specification of Lateral Plate Mesoderm
por: Eng, Diana, et al.
Publicado: (2012)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

A novel PITX2 mutation causing iris hypoplasia
por: Kimura, Masashi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j2u04m9nl1oj7ibi70plp2jm19